We are live on
!
Find out more
Lazard Asset Management Portfolio holdings
AUM
$60.8B
1-Year Est. Return
22.47%
This Fund
S&P 500
This Quarter
Est. Return
+5.89%
1 Year Est. Return
+22.47%
3 Year Est. Return
+62.53%
5 Year Est. Return
+77.87%
10 Year Est. Return
+302.07%
AUM
$47.8B
AUM Growth
+$3.07B
(+6.9%)
Cap. Flow
-$507M
Cap. Flow
% of AUM
-1.06%
Top 10 Holdings %
Top 10 Hldgs %
17.74%
Holding
1,131
New
130
Increased
292
Reduced
306
Closed
143
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Teva Pharmaceuticals
TEVA
|
+$526M |
| 2 |
Ally Financial
ALLY
|
+$198M |
| 3 |
CSX Corp
CSX
|
+$191M |
| 4 |
NetEase
NTES
|
+$173M |
| 5 |
Norwegian Cruise Line
NCLH
|
+$171M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$262M |
| 2 |
CVS Health
CVS
|
+$240M |
| 3 |
Mastercard
MA
|
+$204M |
| 4 |
McKesson
MCK
|
+$201M |
| 5 |
Molson Coors Class B
TAP
|
+$171M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 14.83% |
| 2 | Communication Services | 13.94% |
| 3 | Technology | 12.15% |
| 4 | Financials | 10.5% |
| 5 | Energy | 9.35% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
551
Prologis
PLD
$134B
| $2.03M | ﹤0.01% |
49,476
-32,532
| -40% | -$1.34M |
|
|
TWC
552
DELISTED
TIME WARNER CABLE INC NEW COM STK
TWC
| $2.02M | ﹤0.01% |
13,750
-1,715
| -11% | -$241K |
|
553
Capri Holdings
CPRI
$1.77B
| $2.01M | ﹤0.01% |
22,636
+12,327
| +120% | +$1.13M |
|
554
Trex
TREX
$4.4B
| $2M | ﹤0.01% |
278,248
-736
| -0.3% | -$6.24K |
|
555
T. Rowe Price
TROW
$25.7B
| $2M | ﹤0.01% |
23,645
+23,500
| +16,207% | +$1.92M |
|
|
RKT
556
DELISTED
ROCK-TENN COMPANY CL-A
RKT
| $1.98M | ﹤0.01% |
37,472
-123,452
| -77% | -$6.22M |
|
557
Wipro
WIT
$19.3B
| $1.96M | ﹤0.01% |
879,632
+538,133
| +158% | +$1.21M |
|
558
Vanguard Short-Term Bond ETF
BSV
$44.6B
| – | – |
0
| – | – |
|
559
STAG Industrial
STAG
$7.46B
| $1.94M | ﹤0.01% |
80,900
| – | – |
|
|
PRMW
560
DELISTED
Primo Water Corporation
PRMW
| $1.94M | ﹤0.01% |
274,451
+112,184
| +69% | +$843K |
|
|
PX
561
DELISTED
Praxair Inc
PX
| $1.93M | ﹤0.01% |
14,560
-11
| -0.1% | -$1.44K |
|
|
CAJ
562
DELISTED
Canon, Inc.
CAJ
| $1.91M | ﹤0.01% |
58,475
+4,060
| +7% | +$131K |
|
563
Colgate-Palmolive
CL
$73.9B
| $1.9M | ﹤0.01% |
27,875
-160
| -0.6% | -$10.7K |
|
564
Royce Value Trust
RVT
$2.19B
| $1.9M | ﹤0.01% |
118,752
-29,350
| -20% | -$458K |
|
565
iShares MSCI Brazil ETF
EWZ
$9.01B
| $1.89M | ﹤0.01% |
+39,574
| New | +$1.89M |
|
|
UTIW
566
DELISTED
UTI WORLDWIDE INC
UTIW
| $1.85M | ﹤0.01% |
+179,400
| New | +$1.78M |
|
567
Spectrum Brands
SPB
$2.01B
| $1.84M | ﹤0.01% |
+21,442
| New | +$1.67M |
|
568
Leidos
LDOS
$14.6B
| $1.81M | ﹤0.01% |
+47,207
| New | +$1.79M |
|
569
Zebra Technologies
ZBRA
$13.5B
| $1.8M | ﹤0.01% |
21,858
+19,404
| +791% | +$1.42M |
|
570
Steel Dynamics
STLD
$36.9B
| $1.79M | ﹤0.01% |
+100,000
| New | +$1.8M |
|
571
Royal Bank of Canada
RY
$289B
| $1.78M | ﹤0.01% |
24,900
+21,900
| +730% | +$1.49M |
|
572
Credit Acceptance
CACC
$5.95B
| $1.75M | ﹤0.01% |
14,242
-1,376
| -9% | -$182K |
|
573
Travelers Companies
TRV
$82.5B
| $1.75M | ﹤0.01% |
18,587
+15,929
| +599% | +$1.45M |
|
|
HME
574
DELISTED
HOME PROPERTIES, INC
HME
| $1.73M | ﹤0.01% |
27,000
+6,100
| +29% | +$376K |
|
575
Trinity Industries
TRN
$3B
| $1.69M | ﹤0.01% |
+53,615
| New | +$1.52M |
|
Similar funds
QCM
Lazard Asset Management's Q2 2014 Portfolio in Review
As of Q2 2014, Lazard Asset Management held 1,131 positions worth $47.8B, up 6.9% from $44.8B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Lazard Asset Management's Q2 2014 filing shows 130 new, 292 increased, 306 reduced and 143 closed positions. Its largest new stake was Ally Financial: 8,153,883 shares worth $195M. The largest sale was Gilead Sciences, an estimated $262M.
By sector, the portfolio is most concentrated in Healthcare at 15% of assets, down from 16% a quarter earlier, followed by Communication Services and Technology.
- Lazard Asset Management's largest Q2 2014 buy was Ally Financial: 8,153,883 shares worth $195M.
- Lazard Asset Management added most to Teva Pharmaceuticals in Q2 2014, an estimated $526M increase.
- Lazard Asset Management's biggest Q2 2014 reduction was Gilead Sciences, cutting an estimated $262M.
- Lazard Asset Management fully exited Mastercard in Q2 2014, selling an estimated $204M.
- Lazard Asset Management's ten largest holdings make up 18% of its $47.8B portfolio in Q2 2014.
- Lazard Asset Management opened 130 new positions and closed 143 in Q2 2014.
- Lazard Asset Management's portfolio value rose 6.9% quarter-over-quarter to $47.8B.
Based on Lazard Asset Management's 13F filing for Q2 2014, filed 12 Aug 2014.